199 related articles for article (PubMed ID: 29636998)
21. Crosstalk Between Histone and DNA Methylation in Regulation of Retinal Matrix Metalloproteinase-9 in Diabetes.
Duraisamy AJ; Mishra M; Kowluru RA
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6440-6448. PubMed ID: 29261844
[TBL] [Abstract][Full Text] [Related]
22. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
23. Regulation of T Cell Differentiation and Function by EZH2.
Karantanos T; Chistofides A; Barhdan K; Li L; Boussiotis VA
Front Immunol; 2016; 7():172. PubMed ID: 27199994
[TBL] [Abstract][Full Text] [Related]
24. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
Xu J; Wang Z; Lu W; Jiang H; Lu J; Qiu J; Ye G
Pathol Res Pract; 2019 Jun; 215(6):152374. PubMed ID: 30952377
[TBL] [Abstract][Full Text] [Related]
25. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.
Christofides A; Karantanos T; Bardhan K; Boussiotis VA
Oncotarget; 2016 Dec; 7(51):85624-85640. PubMed ID: 27793053
[TBL] [Abstract][Full Text] [Related]
27. Down-regulated lncRNA MEG3 promotes osteogenic differentiation of human dental follicle stem cells by epigenetically regulating Wnt pathway.
Deng L; Hong H; Zhang X; Chen D; Chen Z; Ling J; Wu L
Biochem Biophys Res Commun; 2018 Sep; 503(3):2061-2067. PubMed ID: 30103943
[TBL] [Abstract][Full Text] [Related]
28. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential.
Gan L; Yang Y; Li Q; Feng Y; Liu T; Guo W
Biomark Res; 2018; 6():10. PubMed ID: 29556394
[TBL] [Abstract][Full Text] [Related]
30. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
Deb G; Thakur VS; Limaye AM; Gupta S
Mol Carcinog; 2015 Jun; 54(6):485-99. PubMed ID: 24481780
[TBL] [Abstract][Full Text] [Related]
32. EZH2 Impairs Human Dental Pulp Cell Mineralization via the Wnt/β-Catenin Pathway.
Li B; Yu F; Wu F; Hui T; A P; Liao X; Yin B; Wang C; Ye L
J Dent Res; 2018 May; 97(5):571-579. PubMed ID: 29294297
[TBL] [Abstract][Full Text] [Related]
33. The possible role of EZH2 and DNMT1 polymorphisms in sporadic triple-negative breast carcinoma in southern Chinese females.
Tao R; Chen Z; Wu P; Liu C; Peng Y; Zhao W; Hu C; Feng J
Tumour Biol; 2015 Dec; 36(12):9849-55. PubMed ID: 26162541
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Gao B; Liu X; Li Z; Zhao L; Pan Y
Front Oncol; 2020; 10():600514. PubMed ID: 33665162
[TBL] [Abstract][Full Text] [Related]
35. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma.
Lv YF; Yan GN; Meng G; Zhang X; Guo QN
Sci Rep; 2015 Aug; 5():12999. PubMed ID: 26265454
[TBL] [Abstract][Full Text] [Related]
36. MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions.
Shi Z; Li Y; Qian X; Hu Y; Liu J; Zhang S; Zhang J
J Cancer; 2017; 8(15):3037-3048. PubMed ID: 28928895
[TBL] [Abstract][Full Text] [Related]
37. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.
Yu T; Wang Y; Hu Q; Wu W; Wu Y; Wei W; Han D; You Y; Lin N; Liu N
Oncotarget; 2017 Nov; 8(58):98348-98359. PubMed ID: 29228694
[TBL] [Abstract][Full Text] [Related]
38. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
[TBL] [Abstract][Full Text] [Related]
39. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
40. Targeting enhancer of zeste homolog 2 protects against acute kidney injury.
Zhou X; Zang X; Guan Y; Tolbert T; Zhao TC; Bayliss G; Zhuang S
Cell Death Dis; 2018 Oct; 9(11):1067. PubMed ID: 30341286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
